Sugi Predict

Sugi Predict / Compounds / SCHEMBL6399524

SCHEMBL6399524

SCHEMBL6399524

CN(C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)OC(C)(C)C)C(Cc1cccs1)CN(C)S(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 8/20 0.47
▸ CTSC P53634 1/20 0.38
▸ CTSB P07858 1/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ BMP1 P13497 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320124 1.00 GHSR (0.47) GHSRCTSCCTSBCTSSCTSK
SCHEMBL3274994 0.85 GHSR (0.51) GHSRCTSCCTSBCTSSCTSK
SCHEMBL8198437 0.84 GHSR (0.58) GHSRCTSCCTSBCTSSCTSK
SCHEMBL8198432 0.84 GHSR (0.58) GHSRCTSCCTSBCTSSCTSK
SCHEMBL6317774 0.84 GHSR (0.69) GHSRCTSCBMP1CYP3A4CYP2D6
SCHEMBL6317787 0.84 GHSR (0.69) GHSRCTSCBMP1CYP3A4CYP2D6
SCHEMBL6316639 0.83 CTSK (0.41) CTSCCTSSCTSKBMP1MMP13
SCHEMBL8906232 0.83 GHSR (0.54) GHSRCTSCBMP1CYP3A4CYP2D6
SCHEMBL8190649 0.82 GHSR (0.51) GHSRCTSCCTSBCTSSCTSK
SCHEMBL8906086 0.81 GHSR (0.43) GHSRCTSCBMP1CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 GHSR 2/4885CTSC 242/4885CTSB 967/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR GHSR 2/4885CTSC 234/4885CTSB 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.